US FTA Lobbying Intensifies

A US business lobby group has restated that drug prices will not rise in Malaysia after the implementation of a US free trade agreement (FTA) and described the pact as a 'win-win' opportunity for both countries. While BMI believes that the enhanced intellectual property environment engendered by the FTA will encourage the evolution of Malaysian research-based drugmakers, particularly biotech start-ups, we are doubtful that medicine prices will not rise. Furthermore, it is BMI's view that negotiations will not be concluded before July, putting the entire FTA in

To read the full article, please choose one of the following options: